8-week Study to Evaluate Safety and Efficacy of Various Combinations of Valsartan, HCTZ, and Amlodipine in Patients With Moderate to Severe Hypertension
Overview
The purpose of this study is to determine the safety and efficacy of the various combinations of valsartan, HCTZ, and amlodipine in patients with moderate to severe hypertension.
Full Title of Study: “An 8-week, Multicenter Study to Evaluate the Efficacy and Safety of the Combination of Valsartan/HCTZ/Amlodipine Compared to Valsartan/HCTZ, Valsartan/Amlodipine, and HCTZ/Amlodipine in Patients With Moderate to Severe Hypertension.”
Study Type
- Study Type: Interventional
- Study Design
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Primary Purpose: Treatment
- Masking: Double
- Study Primary Completion Date: August 2007
Interventions
- Drug: Valsartan + amlodipine
- Drug: Valsartan + HCTZ
- Drug: Amlodipine + HCTZ
- Drug: Valsartan + amlodipine + HCTZ
Clinical Trial Outcome Measures
Primary Measures
- Change from baseline diastolic blood pressure after 8 weeks
- Change from baseline systolic blood pressure after 8 weeks
Secondary Measures
- Blood pressure less than 140/90 mmHg after 8 weeks
- Systolic blood pressure less than 140 mmHg or diastolic blood pressure less than 90 mmHg after 8 weeks
- Diastolic blood pressure less than 90 mmHg or at least a 10 mmHg decrease after 8 weeks or systolic blood pressure less than 140 mmHg or at least a 15 mmHg decrease after 8 weeks
- Ambulatory blood pressure and standing systolic and diastolic blood pressure measurements
- Adverse events, serious adverse events, laboratory values, physical examinations, and vital signs for up to 8 weeks
Participating in This Clinical Trial
Inclusion Criteria
- Diagnosis of moderate to severe hypertension (MSDBP ≥ 100 mmHg and < 120 mmHg, MSSBP ≥ 145 mmHg and < 200 mmHg). Exclusion Criteria:
- Patients on two or more antihypertensive drugs with MSSBP ≥ 180 mmHg and/or MSDBP ≥ 110 mmHg at Visit 1. – Patients on three or more antihypertensive drugs with MSDBP ≥ 90 mmHg and < 110 mmHg, and/or MSSBP ≥ 140 mmHg and < 180 mmHg at Visit 1. – Patients on four or more antihypertensive drugs at Visit 1. – Arm circumference > 42 cm for patients participating in ABPM. Other protocol-defined exclusion criteria may apply.
Gender Eligibility: All
Minimum Age: 18 Years
Maximum Age: 85 Years
Are Healthy Volunteers Accepted: Accepts Healthy Volunteers
Investigator Details
- Lead Sponsor
- Novartis
- Provider of Information About this Clinical Study
- Sponsor
- Overall Official(s)
- Novartis Pharmaceuticals, Principal Investigator, Novartis Pharmaceuticals
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.